THIAMINE-RESPONSIVE MEGALOBLASTIC ANAEMIA WITH HYPOTHYROIDISM, A PUZZLING ASSOCIATION

Authors

  • Versha Rani Rai National Institute of Child Health Karachi- Pakistan
  • Mohsina Noor Ibrahim National Institute of Child Health Karachi- Pakistan
  • Muhammad Nasir Javed National Institute of Child Health Karachi- Pakistan
  • Zubair Khoso National Institute of Child Health Karachi- Pakistan
  • Heeranand Rathore National Institute of Child Health Karachi- Pakistan

DOI:

https://doi.org/10.55519/JAMC-S4-12486

Keywords:

TRMA, HYPOTHYROID, DIABETES MELLITUS, HEARING LOSS, OPTIC NERVE

Abstract

Background: Thiamine-responsive megaloblastic anemia (TRMA) is characterized by the classic trio of diabetes mellitus, sensorineural hearing loss, and megaloblastic anemia, typically emerging subtly between infancy and adolescence. Administration of high-dose thiamine often yields improvements in anemia and occasionally in diabetes. Uncommon manifestations include optic atrophy, congenital heart defects, short stature, and stroke. In this specific case, a 5-year-old diagnosed with insulin-dependent diabetes mellitus (IDDM) since the age of one presented with symptoms such as polyuria, fever, and vomiting, revealing an HbA1c of 10.64. Further examinations disclosed compromised hearing and vision. Negative antibody workup and a thyroid profile indicating hypothyroidism prompted additional investigations, including Brainstem Evoked Response Audiometry (BERA) and retinal examination, confirming bilateral sensorineural hearing loss and maculopathy, respectively. A comprehensive blood count unveiled megaloblastic anemia. Genetic profiling confirmed a homozygous mutation in the SLC19A2 gene, thus diagnosing TRMA. An early diagnosis, coupled with genetic confirmation, enables timely intervention, with patients responding positively to high-dose thiamine. Genetic counseling plays a pivotal role in enlightening families about the disease and its inheritance patterns, fostering awareness and understanding.

Author Biographies

Versha Rani Rai, National Institute of Child Health Karachi- Pakistan

 

Mohsina Noor Ibrahim, National Institute of Child Health Karachi- Pakistan

 

Muhammad Nasir Javed, National Institute of Child Health Karachi- Pakistan

 

Zubair Khoso, National Institute of Child Health Karachi- Pakistan

 

Heeranand Rathore, National Institute of Child Health Karachi- Pakistan

 

References

: Pichler H, Zeitlhofer P, Dworzak MN, Diakos C, Haas OA, Kager L. Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations. European journal of pediatrics. 2012 Nov;171:1711-5.

: Mathews L, Narayanadas K, Sunil G. Thiamine responsive megaloblastic anemia. Indian pediatrics. 2009 Feb 1;46(2).

: Marcé‐Grau A, Martí‐Sánchez L, Baide‐Mairena H, Ortigoza‐Escobar JD, Pérez‐Dueñas B. Genetic defects of thiamine transport and metabolism: a review of clinical phenotypes, genetics, and functional studies. Journal of inherited metabolic disease. 2019 Jul;42(4):581-97.

: Shaw‐Smith C, Flanagan SE, Patch AM, Grulich‐Henn J, Habeb AM, Hussain K, Pomahacova R, Matyka K, Abdullah M, Hattersley AT, Ellard S. Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine‐responsive megaloblastic anaemia. Pediatric diabetes. 2012 Jun;13(4):314-21.

: Sako S, Tsunogai T, Oishi K. Thiamine-responsive megaloblastic anemia syndrome.

: Karimzadeh P, Moosavian T, Moosavian H. Recurrent stroke in a child with TRMA syndrome and SLC19A2 gene mutation. Iranian Journal of Child Neurology. 2018;12(1):84.

Kang P, Zhang W, Wen J, Zhang J, Li F, Sun W. Case report: genetic and clinical features of maternal uniparental isodisomy-induced thiamine-responsive megaloblastic anemia syndrome. Frontiers in Pediatrics. 2021 Mar 19;9:630329.

Downloads

Published

2024-01-16